BRPI0821248A2 - Inibidores de cinesina como fármacos terapêuticos para câncer - Google Patents

Inibidores de cinesina como fármacos terapêuticos para câncer

Info

Publication number
BRPI0821248A2
BRPI0821248A2 BRPI0821248-1A BRPI0821248A BRPI0821248A2 BR PI0821248 A2 BRPI0821248 A2 BR PI0821248A2 BR PI0821248 A BRPI0821248 A BR PI0821248A BR PI0821248 A2 BRPI0821248 A2 BR PI0821248A2
Authority
BR
Brazil
Prior art keywords
cancer drugs
therapeutic cancer
kinesin inhibitors
kinesin
inhibitors
Prior art date
Application number
BRPI0821248-1A
Other languages
English (en)
Inventor
Tinya Abrams
Paul Barsanti
David Duhl
Michel Faure
Paul A Renhowe
Annette Olga Walter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0821248(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0821248A2 publication Critical patent/BRPI0821248A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
BRPI0821248-1A 2007-12-14 2008-12-12 Inibidores de cinesina como fármacos terapêuticos para câncer BRPI0821248A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14
PCT/EP2008/067412 WO2009077448A1 (en) 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics

Publications (1)

Publication Number Publication Date
BRPI0821248A2 true BRPI0821248A2 (pt) 2015-06-16

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821248-1A BRPI0821248A2 (pt) 2007-12-14 2008-12-12 Inibidores de cinesina como fármacos terapêuticos para câncer

Country Status (30)

Country Link
US (2) US8252832B2 (pt)
EP (1) EP2229170B1 (pt)
JP (1) JP5501976B2 (pt)
KR (1) KR20100098394A (pt)
CN (1) CN101939005B (pt)
AR (1) AR069676A1 (pt)
AU (1) AU2008337570B2 (pt)
BR (1) BRPI0821248A2 (pt)
CA (1) CA2708822A1 (pt)
CL (1) CL2008003707A1 (pt)
CO (1) CO6290651A2 (pt)
CR (1) CR11412A (pt)
DO (1) DOP2010000175A (pt)
EA (1) EA018014B1 (pt)
EC (1) ECSP10010248A (pt)
ES (1) ES2459442T3 (pt)
GE (1) GEP20125647B (pt)
GT (1) GT201000172A (pt)
IL (1) IL205831A0 (pt)
MA (1) MA31872B1 (pt)
MY (1) MY150214A (pt)
NI (1) NI201000091A (pt)
NZ (1) NZ585142A (pt)
PA (1) PA8807801A1 (pt)
PE (1) PE20091451A1 (pt)
SM (1) SMP201000095B (pt)
TN (1) TN2010000204A1 (pt)
TW (1) TW200930704A (pt)
UY (1) UY31532A1 (pt)
WO (1) WO2009077448A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
JP2013525290A (ja) * 2010-04-15 2013-06-20 ノバルティス アーゲー Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
CN105451773A (zh) * 2013-03-15 2016-03-30 诺华股份有限公司 细胞增殖抑制剂及其缀合物
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
CN114917361A (zh) * 2015-06-22 2022-08-19 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
JP2010515687A (ja) 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体

Also Published As

Publication number Publication date
GT201000172A (es) 2012-04-30
DOP2010000175A (es) 2010-06-30
CO6290651A2 (es) 2011-06-20
GEP20125647B (en) 2012-09-25
PA8807801A1 (es) 2009-07-23
CL2008003707A1 (es) 2009-06-05
JP2011506402A (ja) 2011-03-03
US8664256B2 (en) 2014-03-04
ES2459442T3 (es) 2014-05-09
TN2010000204A1 (en) 2011-11-11
NZ585142A (en) 2012-03-30
IL205831A0 (en) 2010-11-30
US20090239922A1 (en) 2009-09-24
ECSP10010248A (es) 2010-07-30
WO2009077448A1 (en) 2009-06-25
TW200930704A (en) 2009-07-16
US8252832B2 (en) 2012-08-28
EP2229170A1 (en) 2010-09-22
US20130012560A1 (en) 2013-01-10
AU2008337570A1 (en) 2009-06-25
EP2229170B1 (en) 2014-01-22
CR11412A (es) 2010-06-30
MA31872B1 (fr) 2010-11-01
NI201000091A (es) 2011-03-15
SMP201000095B (it) 2011-09-09
UY31532A1 (es) 2009-08-03
EA018014B1 (ru) 2013-04-30
JP5501976B2 (ja) 2014-05-28
SMAP201000095A (it) 2010-09-10
AU2008337570B2 (en) 2012-04-05
CN101939005A (zh) 2011-01-05
AR069676A1 (es) 2010-02-10
PE20091451A1 (es) 2009-10-19
CA2708822A1 (en) 2009-06-25
CN101939005B (zh) 2015-12-16
MY150214A (en) 2013-12-13
KR20100098394A (ko) 2010-09-06
EA201000900A1 (ru) 2011-02-28

Similar Documents

Publication Publication Date Title
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
DK2121139T3 (da) Formulations for cancer treatment
BRPI0821779A2 (pt) tratamento terapêutico de câncer
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BR112012005594A2 (pt) tratamento de câncer
BRPI0821316A2 (pt) Adaptador antioclusão para cateter
BRPI0808191A2 (pt) dispositivos implantáveis híbridos terapêuticos
BRPI1006438A2 (pt) terapia adjuvante de cancer
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
BRPI0813670A2 (pt) Compostos para tratamento
BRPI1008664A2 (pt) comprimidos para a terapia de combinação
BRPI0922884A2 (pt) compostos para tratamento de câncer
DK2219683T3 (da) Målrettet radioterapi
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0813789A2 (pt) Potenciação de quimioterapia contra câncer
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
DK2437736T3 (da) Lægemiddelindgivelsessystemer
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.